206 related articles for article (PubMed ID: 19342366)
1. Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases.
Neuwirt H; Puhr M; Santer FR; Susani M; Doppler W; Marcias G; Rauch V; Brugger M; Hobisch A; Kenner L; Culig Z
Am J Pathol; 2009 May; 174(5):1921-30. PubMed ID: 19342366
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways.
Puhr M; Santer FR; Neuwirt H; Susani M; Nemeth JA; Hobisch A; Kenner L; Culig Z
Cancer Res; 2009 Sep; 69(18):7375-84. PubMed ID: 19738059
[TBL] [Abstract][Full Text] [Related]
3. [Androgens stimulate the expression of SOCS-3 and inhibits their effect on proliferation and secretion].
Neuwirt H; Puhr M; Cavarretta IT; Mitterberger M; Hobisch A; Culig Z
Aktuelle Urol; 2009 Aug; 40(4):231-4. PubMed ID: 19634073
[TBL] [Abstract][Full Text] [Related]
4. Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer.
Bellezza I; Neuwirt H; Nemes C; Cavarretta IT; Puhr M; Steiner H; Minelli A; Bartsch G; Offner F; Hobisch A; Doppler W; Culig Z
Am J Pathol; 2006 Dec; 169(6):2199-208. PubMed ID: 17148681
[TBL] [Abstract][Full Text] [Related]
5. Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion.
Neuwirt H; Puhr M; Cavarretta IT; Mitterberger M; Hobisch A; Culig Z
Endocr Relat Cancer; 2007 Dec; 14(4):1007-19. PubMed ID: 18045952
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
7. The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling.
Correa RG; Krajewska M; Ware CF; Gerlic M; Reed JC
Oncotarget; 2014 Mar; 5(6):1666-82. PubMed ID: 24681825
[TBL] [Abstract][Full Text] [Related]
8. SOCS-3 is downregulated in progressive CKD patients and regulates proliferation in human renal proximal tubule cells in a STAT1/3 independent manner.
Neuwirt H; Eder IE; Puhr M; Rudnicki M
Lab Invest; 2013 Jan; 93(1):123-34. PubMed ID: 23108375
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of G1-S cyclins and cyclin-dependent kinases during multistage human pancreatic duct cell carcinogenesis.
Al-Aynati MM; Radulovich N; Ho J; Tsao MS
Clin Cancer Res; 2004 Oct; 10(19):6598-605. PubMed ID: 15475449
[TBL] [Abstract][Full Text] [Related]
10. Suppressor of cytokine signaling (SOCS) genes are silenced by DNA hypermethylation and histone deacetylation and regulate response to radiotherapy in cervical cancer cells.
Kim MH; Kim MS; Kim W; Kang MA; Cacalano NA; Kang SB; Shin YJ; Jeong JH
PLoS One; 2015; 10(4):e0123133. PubMed ID: 25849377
[TBL] [Abstract][Full Text] [Related]
11. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
12. ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo.
Casimiro M; Rodriguez O; Pootrakul L; Aventian M; Lushina N; Cromelin C; Ferzli G; Johnson K; Fricke S; Diba F; Kallakury B; Ohanyerenwa C; Chen M; Ostrowski M; Hung MC; Rabbani SA; Datar R; Cote R; Pestell R; Albanese C
Cancer Res; 2007 May; 67(9):4364-72. PubMed ID: 17483350
[TBL] [Abstract][Full Text] [Related]
13. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.
Le Magnen C; Bubendorf L; Ruiz C; Zlobec I; Bachmann A; Heberer M; Spagnoli GC; Wyler S; Mengus C
Eur J Cancer; 2013 Mar; 49(4):955-63. PubMed ID: 23089465
[TBL] [Abstract][Full Text] [Related]
14. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
15. SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling.
Puhr M; Santer FR; Neuwirt H; Marcias G; Hobisch A; Culig Z
Endocr Relat Cancer; 2010 Jun; 17(2):525-38. PubMed ID: 20335309
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of signal transducer and activator of transcription (STAT-3 and STAT-5) transcription factors and alteration of suppressor of cytokine signaling (SOCS-1) protein in prostate cancer.
Singh N; Hussain S; Bharadwaj M; Kakkar N; Singh SK; Sobti RC
J Recept Signal Transduct Res; 2012 Dec; 32(6):321-7. PubMed ID: 23134344
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the roles of suppressor of cytokine signaling-3 in prostate cancer development and progression.
Fu X; Ren L; Chen J; Liao K; Fu Y; Qian X; Xiao J
Asia Pac J Clin Oncol; 2015 Jun; 11(2):106-13. PubMed ID: 25899712
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of drs mRNA in human prostate carcinomas.
Kim CJ; Shimakage M; Kushima R; Mukaisho K; Shinka T; Okada Y; Inoue H
Hum Pathol; 2003 Jul; 34(7):654-7. PubMed ID: 12874760
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone down-regulation of Interleukin-1beta and Interleukin-6 induced acute phase protein gene expression is associated with increased gene expression of suppressor of cytokine signal-3.
Wu X; Herndon DN; Wolf SE
Shock; 2003 Apr; 19(4):314-20. PubMed ID: 12688541
[TBL] [Abstract][Full Text] [Related]
20. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
